Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

Summary

The purpose of this study was to assess whether the topical use of SD-101 cream (3% or 6%) was effective in treating wounds in participants with Simplex, Recessive Dystrophic, or Junctional non-Herlitz Epidermolysis Bullosa (EB).

Timeline

Start

2014-01-06

Primary completion

2014-06-24

Completion

2014-06-24

Outcome

Missed primary endpoint

registry analysis (superiority test); SD-101 Dermal Cream (6%) vs Vehicle (0%); p =0.3699; Fisher Exact NCT02014376 ↗

Drugs

Indications